Ariad Pharmaceuticals Inc - Strategic SWOT Analysis Review

  • ID: 4429758
  • SWOT Analysis
  • 39 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • Amgen Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Eli Lilly and Co
  • Merck & Co Inc
  • Mirati Therapeutics Inc
  • MORE
Ariad Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Summarization of the company’s business strategy.
  • SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
Highlights

Ariad Pharmaceuticals Inc (Ariad), a subsidiary of Takeda Pharmaceutical Company Limited focuses on the discovery, development and marketing of small-molecule oncology therapies. Its products are indicated to treat chronic and acute leukemia, lung cancer and other difficult to treat cancers. The company’s lead product, Iclusig (ponatinib) is indicated for the treatment of chronic myeloid leukemia (CML). Ariad’s pipeline portfolio comprises three promising molecules including Iclusig, a novel oral multi-targeted kinase inhibitor; Brigatinib, an anaplastic lymphoma kinase inhibitor; and AP32788, a drug candidate, for the treatment of patients with NSCLC with specific mutations in the EGFR or HER2 kinases. Ariad is headquartered in Cambridge, Massachusetts, the US.

Ariad Pharmaceuticals Inc Key Recent Developments

Nov 07, 2016: ARIAD Reports Third Quarter 2016 Financial Results
Oct 20, 2016: ARIAD Reaffirms Commitment to Discovering and Developing Treatments for Patients with Rare Cancers
Jul 28, 2016: ARIAD Reports Second Quarter and First Half 2016 Financial Results
Jun 17, 2016: ARIAD Completes Strategic Review and Announces Plans for Growth
May 24, 2016: ARIAD Announces Appointment of Jennifer L. Herron as Chief Commercial Officer

Reasons to Buy
  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with this detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Eli Lilly and Co
  • Merck & Co Inc
  • Mirati Therapeutics Inc
  • MORE
Section 1 - About the Company
  • Ariad Pharmaceuticals Inc - Key Facts
  • Ariad Pharmaceuticals Inc - Key Employees
  • Ariad Pharmaceuticals Inc - Major Products and Services
  • Ariad Pharmaceuticals Inc - History
  • Ariad Pharmaceuticals Inc - Company Statement
  • Ariad Pharmaceuticals Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Ariad Pharmaceuticals Inc - Business Description
  • Ariad Pharmaceuticals Inc - Corporate Strategy
  • Ariad Pharmaceuticals Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Ariad Pharmaceuticals Inc - Strengths
  • Ariad Pharmaceuticals Inc - Weaknesses
  • Ariad Pharmaceuticals Inc - Opportunities
  • Ariad Pharmaceuticals Inc - Threats
  • Ariad Pharmaceuticals Inc - Key Competitors
Section 3 - Company’s Lifesciences Financial Deals and Alliances
  • Ariad Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
  • Ariad Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
  • Ariad Pharmaceuticals Inc, Recent Deals Summary
Section 4 - Company’s Recent Developments
  • Nov 07, 2016: ARIAD Reports Third Quarter 2016 Financial Results
  • Oct 20, 2016: ARIAD Reaffirms Commitment to Discovering and Developing Treatments for Patients with Rare Cancers
  • Jul 28, 2016: ARIAD Reports Second Quarter and First Half 2016 Financial Results
  • Jun 17, 2016: ARIAD Completes Strategic Review and Announces Plans for Growth
  • May 24, 2016: ARIAD Announces Appointment of Jennifer L. Herron as Chief Commercial Officer
  • May 10, 2016: ARIAD Reports First Quarter 2016 Financial Results and Progress on Strategic Review
  • Mar 29, 2016: ARIAD Announces Reduction in Workforce as Part of Ongoing Company-Wide Strategic Review
  • Mar 22, 2016: ARIAD Reports Inducement Grant to New Chief Financial Officer
  • Mar 11, 2016: ARIAD Announces Appointment of Manmeet S. Soni as Chief Financial Officer
  • Feb 23, 2016: ARIAD Reports 2015 Financial Results, Provides 2016 Product Revenue Guidance and Outlines Company Progress
Section 5 - Appendix
  • Methodology
List of Tables
  • Ariad Pharmaceuticals Inc, Key Facts
  • Ariad Pharmaceuticals Inc, Key Employees
  • Ariad Pharmaceuticals Inc, Major Products and Services
  • Ariad Pharmaceuticals Inc, History
  • Ariad Pharmaceuticals Inc, Subsidiaries
  • Ariad Pharmaceuticals Inc, Key Competitors
  • Ariad Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
  • Ariad Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
  • Ariad Pharmaceuticals Inc, Recent Deals Summary
List of Figures
  • Ariad Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
  • Ariad Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • TG Therapeutics Inc
  • Tesaro Inc
  • Mirati Therapeutics Inc
  • Merck & Co Inc
  • Ligand Pharmaceuticals Inc
  • Eli Lilly and Co
  • Bristol-Myers Squibb Co
  • AstraZeneca Plc
  • Amgen Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll